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MaBACKGROUND Bioresorbable scaffolds provide transient lumen support followed by complete resorption.
OBJECTIVES This study examined whether very late scaffold thrombosis (VLScT) occurs when resorption is presumed
to be nearly complete.
METHODS Patients with VLScT at 3 tertiary care centers underwent thrombus aspiration followed by optical
coherence tomography (OCT). Thrombus aspirates were analyzed by histopathological and spectroscopic
examination.
RESULTS Between March 2014 and February 2015, 4 patients presented with VLScT at 44 (case 1), 19 (cases 2 and 4),
and 21 (case 3) months, respectively, after implantation of an Absorb Bioresorbable Vascular Scaffold 1.1 (Abbott Lab-
oratories, Abbott Park, Illinois). At the time of VLScT, all patients were taking low-dose aspirin, and 2 patients were also
taking prasugrel. OCT showed malapposed scaffold struts surrounded by thrombus in 7.1%, 9.0%, and 8.9% of struts in
cases 1, 2, and 4, respectively. Scaffold discontinuity with struts in the lumen center was the cause of malapposition in
cases 2 and 4. Uncovered scaffold struts with superimposed thrombus were the predominant ﬁndings in case 3. OCT
percent area stenosis at the time of VLScT was high in case 1 (74.8%) and case 2 (70.9%) without evidence of excessive
neointimal hyperplasia. Spectroscopic thrombus aspirate analysis showed persistence of intracoronary polymer frag-
ments in case 1.
CONCLUSIONS VLScT may occur at advanced stages of scaffold resorption. Potential mechanisms speciﬁc for
VLScT include scaffold discontinuity and restenosis during the resorption process, which appear delayed in humans;
these ﬁndings suggest an extended period of vulnerability for thrombotic events. (J AmColl Cardiol 2015;66:1901–14)
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ABBR EV I A T I ON S
AND ACRONYMS
BVS = bioresorbable vascular
scaffold
CAD = coronary artery disease
DAPT = dual antiplatelet
therapy
DES = drug-eluting stent(s)
IR = infrared
LCX = left circumﬂex artery
OCT = optical coherence
tomography
RVD = reference vessel
diameter
VLScT = very late scaffold
thrombosis
VLST = very late stent
thrombosis
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1902M etallic drug-eluting stents (DES)have improved clinical outcomesof patients undergoing percuta-
neous coronary interventions (PCIs)
compared with balloon angioplasty and
bare-metal stents (1). Although newer-
generation metallic DES have further
advanced the safety and efﬁcacy proﬁle
compared with ﬁrst-generation devices
(2–4), the persistence of a metallic cage has
been suggested to prevent complete arterial
healing. Fully bioresorbable scaffolds have
been introduced into clinical practice (5),
with the objectives of preserving native
vessel geometry, providing for adaptive
vessel remodeling with late lumen gain (6),
restoring physiological vasomotion (7), and
avoiding late adverse events including reste-nosis and thrombosis (8).SEE PAGE 1915The Absorb bioresorbable vascular scaffold (BVS)
(Abbott Laboratories, Abbott Park, Illinois) consists of
a poly (L-lactide acid) (PLLA) polymer backbone, a
coating layer of poly (D,L-lactide acid), and the anti-
restenotic drug everolimus. The clinically available
Absorb BVS 1.1 has in-phase zigzag hoops linked with
bridges, providing improved vessel wall support and
delayed resorption to preserve the mechanical
integrity over at least 6 months (9,10). The Absorb
BVS 1.1 has been compared with newer-generation
metallic DES in 2 randomized trials to date. In the
EVERBIO II (second Everolimus-Versus Biolimus-
Eluting Stents in All-Comers) study, similar efﬁcacy
was seen at 9-month angiographic follow-up for the
Absorb BVS as with the combined group receiving
either a metallic everolimus-eluting stent (Promus
Element, Boston Scientiﬁc Corporation, Marlborough,
Massachusetts) or a biodegradable polymer biolimus-
eluting stent (Biomatrix Flex, Biosensors Interna-
tional, Singapore) (11). Similar clinical efﬁcacy at
1 year was also reported in the ABSORB II trial (A
Clinical Evaluation of the Bioabsorbable Everolimus
Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Le-
sions) comparing metallic everolimus-eluting stents
with the Absorb BVS (12). Several reports have
described the occurrence of predominantly early
scaffold thrombosis, potentially related to the strut
thickness of 150 mm and highlighting technical con-
siderations regarding lesion preparation, scaffold
expansion, and optimal antiplatelet therapy (13–15).
Conversely, very late scaffold thrombosis (VLScT),
more than 1 year after device implantation, has beenreported only in isolated case reports (16–18). We
aimed to characterize fully 4 cases of VLScT observed
at 3 tertiary care centers by means of quantitative
coronary angiography (QCA), optical coherence to-
mography (OCT), histopathological examination, and
spectroscopic analysis of thrombus aspirates.
METHODS
All patients presenting with very late (>1 year) scaf-
fold thrombosis after BVS (Absorb BVS 1.1, Abbott
Vascular, Santa Clara, California) implantation at
Bern University Hospital, Switzerland, Triemlispital,
Zurich, Switzerland, and University Hospital Clinic of
Barcelona, Spain were included in the present study
and underwent quantitative coronary angioplasty
analysis (all cases), OCT after thrombus aspiration (all
cases), and histopathological (cases 1 to 3) and spec-
troscopic assessment (case 1) of the thrombus
aspirate.
OPTICAL COHERENCE TOMOGRAPHY. OCT was per-
formed using a commercially available system
(C7-XR, Dragon Fly, LightLab, St. Jude Medical,
St. Paul, Minnesota). All recorded data were sent
to a core laboratory (Bern University Hospital,
Switzerland) and were analyzed by a group of
3 experienced analysts (L.R., K.Y., M.T.) at an
interval of 0.2 mm by using dedicated software
(QCU-CMS version 4.69, LKEB, Leiden University, the
Netherlands).
The lumen contour was drawn by semiautomated
detection using QCU-CMS software, following the
endoluminal contour of the neointima with manual
correction wherever required. In case of thrombus
with low attenuation, the lumen contour could still be
drawn. In case of high attenuation, the lumen contour
was extrapolated when the lumen contour was visible
in at least 3 quadrants. The scaffold area was
measured by joining the middle points of the signal-
poor core of the abluminal side of the struts if at
least 1 strut was clearly visible in every quadrant.
Distal and proximal reference area and scaffold
expansion were calculated as previously reported by
the MUSIC (Multicenter Ultrasound Stenting in Cor-
onaries) investigators (6). The neointimal thickness
was measured from the abluminal border of the black
strut core to the lumen. Uncovered struts were
deﬁned in the absence of a homogenous coverage by
neointima. If the apposed struts were not covered by
neointima but rather by irregular tissue, struts were
categorized as “apposed uncovered with super-
imposed thrombus.” Malapposed struts were deﬁned
as struts where the abluminal surface was clearly
separated from the vessel wall.
TABLE 1 Clinical and Procedural Characteristics
Case 1 Case 2 Case 3 Case 4
Clinical characteristics at the
index procedure
Age at index procedure, yrs 68 53 55 55
Male Y Y Y Y
Body mass index, kg/m2 30.9 38.5 22.9 32.1
Hypertension Y Y Y Y
Smoking history N Y N Y
Current smoker N N N N
Dyslipidemia Y Y N Y
Diabetes Y N Y Y
LVEF function Normal Normal Normal Normal
Clinical indication for the index PCI Stable
angina
Stable
angina
NSTE-
ACS
Stable
angina
Number of vessels treated 1 2 1 2
Procedure characteristics at the
index procedure
Target vessel LCX RCA LCX LCX
Lesion type A B1 B2 B2
Scaffold diameter, mm 3.0 3.0 2.5 3.5
Scaffold length, mm 18 18 28 12
Implantation pressure, atm 10 10 16 14
Post-dilation Y N N N
Post-dilation balloon diameter, mm 3.25 - - -
Post-dilation balloon length, mm 15 - - -
Post-dilation balloon pressure, atm 16 - - -
TIMI ﬂow (pre) 3 3 0 3
TIMI ﬂow (post) 3 3 3 3
Clinical and angiographic characteristics
at time point of VLScT
Time between the index PCI and VLScT, months 44 19 21 19
STEMI at time point of VLScT Y Y N Y
Time between symptom onset and
revascularization
4 h 3 days* 22 h 2 h
LV function at time point of VLScT, % 50 N/A 60 50
TIMI ﬂow at time point of VLScT 0 0 0 0
Medications at discharge
Aspirin Y Y Y Y
Clopidogrel Y Y N N
Prasugrel N N Y Y
Statin Y Y Y Y
Medications at time point of VLScT
Aspirin Y Y Y Y
Clopidogrel N N N N
Prasugrel N N Y Y
Statin N Y Y Y
*Diagnosis of STEMI was not established at referring hospital but only after admission to Barcelona University
Hospital, Barcelona, Spain.
LCX ¼ left circumﬂex artery; LVEF ¼ left ventricular ejection fraction; NSTE-ACS ¼ non–ST-segment elevation
acute coronary syndrome; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; STEMI ¼ ST-
segment elevation myocardial infarction; TIMI ¼ Thrombolysis In Myocardial Infarction; VLScT ¼ very late
scaffold thrombosis.
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measured from the abluminal border of the strut core
to the vessel wall. If malapposed struts were partially
or completely surrounded by thrombus, struts were
regarded as malapposed with thrombus. The area
between the backside of the struts and the vessel wall
was measured as the incomplete scaffold apposition
area, whereas the neointimal area was measured as
the scaffold area  (lumen area  incomplete scaffold
apposition area). Intracoronary thrombus was iden-
tiﬁed as any irregular mass inside the lumen, with a
sharp border and various degrees of attenuation.
Volumetric data were retrieved from the DICOM
(Digital Imaging and Communications in Medicine)
dataset using Pydicom package version 0.9.8 on Py-
thon version 2.7.9. Volumetric data and 2-dimensional
OCT data were integrated into density ﬁles (df3
format). The vessel wall outside the lumen was coded
as yellow and the intraluminal material as red. Sur-
faces of the strut core were identiﬁed; malapposed
struts were coded as dark blue, and apposed struts
were coded as light blue.
HISTOPATHOLOGICAL AND SPECTROSCOPIC ANALYSIS.
Specimens were received ﬁxed in 10% neutral buff-
ered formalin. Samples were ﬁltered through a 40-mm
nylon cell strainer. The material collected was
embedded in parafﬁn and stained with hematoxylin
and eosin (H&E), Movat pentachrome, and Periodic
acid–Schiff stain. Independent pathologists (T.K.,
M.J.) evaluated the sections for the composition and
age of thrombus and the presence of foreign material
by using light microscopy and polarized light.
The tissue sample was examined under a stereo-
microscope and a polarizing light microscope. The
area of interest was located, and portions of the
sample were pressed onto a potassium bromide
crystal for infrared (IR) analysis (McCrone Associates,
Inc., Westmont, Illinois). The inclusion from the tis-
sue sample was isolated with a tungsten needle and
was rinsed with nonane to remove the mounting wax.
A commercially available Absorb BVS sample was
analyzed in vitro as reference and showed an IR
spectrum of the Absorb BVS sample similar to a
reference sample of PLLA.
STATISTICAL ANALYSIS. Continuous variables are
reported as mean  SD, whereas categorical values
are presented as absolute values and percentages.
Only descriptive statistics are provided.
RESULTS
During the study period, 171 patients underwent
revascularization using Absorb BVS at the 3 sites;
4 patients experienced VLScT and are described indetail in this case series. Clinical and procedural
characteristics of all cases are presented in Table 1,
quantitative coronary angioplasty results in Table 2,
and quantitative OCT ﬁndings in Table 3.
CASE 1. A type A lesion of the midleft circumﬂex ar-
tery (LCX) in a patient with stable coronary artery
TABLE 2 Quantitative Coronary Angiography
Case 1 Case 2 Case 3 Case 4
Before baseline PCI
Reference vessel diameter, mm 3.13 2.95 2.43 3.35
MLD, mm 1.56 1.26 0.00 1.30
Diameter stenosis, % 50.2 57.3 100 61.3
Lesion length, mm 8.3 23.5 29.1 14.0
After baseline PCI
In-segment
Reference diameter, mm 3.08 2.80 2.71 3.48
MLD, mm 2.51 2.17 2.17 2.55
Diameter stenosis, % 18.6 22.9 19.7 26.7
Acute gain, mm 0.95 0.91 2.17 1.25
In-scaffold
Reference diameter, mm 3.08 2.81 2.71 3.48
MLD, mm 2.51 2.22 2.17 2.55
Diameter stenosis, % 18.6 20.9 19.7 26.7
Acute gain, mm 0.95 0.96 2.17 1.25
Acute recoil, mm 0.16 0.35 0.28 0.69
Acute recoil, % 6.0 13.6 11.4 21.3
MLD ¼ minimal lumen diameter; PCI ¼ percutaneous coronary intervention.
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1904disease (CAD) was treated with a 3.0  18 mm Absorb
BVS 1.1. The angiographic reference vessel diameter
(RVD) was 3.13 mm, and after post-dilation with a
3.25-mm balloon (Table 1, Figure 1), a diameter ste-
nosis of 18.6% remained (Table 2). VLScT occurred
44 months after scaffold implantation with aspirin
monotherapy (Figure 1).
OCT was performed after successful thrombus
aspiration with establishment of Thrombosis in
Myocardial Ischemia Trial (TIMI) ﬂow grade 3 and
after glycoprotein IIb/IIIa administration. In 94% of
analyzed frames, scaffold remnants could be detected
(Figure 2). The OCT-derived percent lumen area ste-
nosis was 74.5%, corresponding to a restenosis of
60% considering the post-procedural minimal lumen
diameter at baseline (Figure 3). The restenosis process
was not related to neointimal hyperplasia (mean
neointimal thickness 0.17  0.10 mm). The main
scaffold strut-related ﬁnding was a high frequency of
malapposed struts (7.4%) with the majority sur-
rounded by thrombus (7.1%) (Table 3). Uncovered
struts persisted in 2.6%, with one-half of them
covered by thrombus. Regarding neoatherosclerosis,
macrophage accumulations were observed in the
neointima (Online Figure 1).
Thrombus aspirates consisted of multiple particles
and showed a ﬁbrin- and platelet-rich thrombus.
Mild mononuclear cell inﬁltration was observed
throughout all particles without presence of eosino-
philic cells (Figure 4A). One particle showed evidence
of foreign material (Figure 5). The foreign material
stained eosinophilic using H&E (Figure 5C) and greenusing Movat pentachrome stain (Figure 5D). Polarized
light showed positive birefringence within the foreign
material (Figure 5E), whereas it stained magenta pink
after Periodic acid–Schiff reaction (Figure 5B). Fourier
transform IR spectroscopy of the foreign material
observed within the thrombus aspirate specimen dis-
played bands similar to a reference sample of the
Absorb BVS 1.1 (Figure 6), as well as in additional bands
that are consistent with protein. Therefore, the in-
clusion of foreign material in the thrombus aspirate is
consistent with persistent remnants of Absorb BVS 1.1.
CASE 2. A type B1 lesion of the midright coronary
artery in a patient with stable CAD was treated with a
3.0  18 mm Absorb BVS 1.1 without post-dilation.
The angiographic RVD was 2.95 mm, and a remain-
ing diameter stenosis of 19.7% was observed (Figure 1,
Table 2). VLScT occurred 19 months after the index
procedure with aspirin monotherapy.
The OCT-derived percent lumen area stenosis was
71%, corresponding to a restenosis of 57% when tak-
ing into account the post-procedure angiographic
minimal lumen diameter, again without noticeable
neointimal hyperplasia (0.21  0.13 mm). Malapposed
struts were frequent (10.3%), with the majority sur-
rounded by thrombus. The main ﬁnding was a scaf-
fold discontinuity with malapposed scaffold struts
located in the middle of the lumen (Figure 2, Online
Video 1). A visualization by 3-dimensional color-
coded spread-out images is shown in Figure 2B. No
malapposition was present in the intravascular ul-
trasound pullback acquired immediately after the
index procedure (Online Figure 2). Uncovered struts
with or without superimposed thrombus were pre-
sent in 6.1% (Table 3). Macrophage accumulations
within the neointima were observed in 20 of 99
frames (20.2%) (Online Figure 1).
Thrombus aspirates consisted of multiple particles
and showed a platelet-rich thrombus with inter-
spersed ﬁbrin deposition. Moderate mononuclear cell
inﬁltration was observed without the presence of
eosinophilic cells (Figure 4B).
CASE 3. A long type B2 lesion of the LCX in a patient
with stable non–ST-segment elevation acute coronary
syndrome was treated with a 2.5  28 mm BVS
without post-dilation. The RVD measured 2.43 mm,
and the diameter stenosis after scaffold implantation
was 19.7%. VLScT occurred 21 months after the index
procedure despite continued dual antiplatelet ther-
apy (DAPT) consisting of prasugrel and aspirin.
OCT-derived lumen area stenosis was <50%. In
contrast to all other cases, malapposition was absent
in case 3, and the predominant ﬁndings consisted of
uncovered scaffold struts (4.7%) (Table 3, Figure 2).
FIGURE 1 Serial Angiography
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In each case, angiography was performed before bioresorbable vascular scaffold (BVS) implantation (A, D, G, J), after implantation (B, E, H, K),
and at the time of very late scaffold thrombosis (C, F, I, L). The orange line is the position of the implanted BVS with subsequent very late
scaffold thrombosis; the blue line indicates the position of 2 implanted BVS without subsequent very late scaffold thrombosis.
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FIGURE 2 Representative OCT Cross Sections and 3D Reconstructions
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Continued on the next page
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FIGURE 3 Minimal Lumen and Scaffold Areas
Case 1 Case 2
Case 3 Case 4
Minimal lumen and scaffold areas, as well as proximal and distal reference vessel segments, are shown by optical coherence tomography cross section for each case.
Scaffold and thrombus region is indicated by color above the longitudinal optical coherence tomography view.
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(>4 mm2) and showed erythrocyte- and ﬁbrin-rich
thrombus. Minimal mononuclear cell inﬁltration was
observed by light microscopy of samples stained
with H&E without the presence of eosinophilic cells
(Figure 4C).
CASE 4. In this stable patient with 2-vessel CAD, the
left anterior descending artery and the LCX were
treated with Absorb BVS, the latter using a 3.5  12 mm
scaffold in the proximal part (B2 lesion) and a
large second marginal with 2 overlapping scaffolds
(Figure 2). The angiographic RVD of the proximal
LCX lesion was 3.35 mm, and after BVS Absorb im-
plantation without post-dilation, a diameter stenosisThe optical coherence tomography (OCT) cross sections were matched w
in A to F). In all cases, D shows the longitudinal view, E the half-cut 3D
(A, B, arrowheads) and the presence of macrophage accumulations at t
(B, arrowheads) (Online Video 1) on 2D and 3D optical coherence tomog
Case 4 shows a scaffold strut discontinuity (A, B, arrowheads) (Online Vid
coherence tomography. Yellow represents the lumen contour; blue is th
FIGURE 2 Continuedof 26.7% was measured. The patient continued DAPT
with prasugrel and aspirin until VLScT occurred at 19
months. No thrombus material was available for
histopathological analysis. The OCT-derived percent
area stenosis was 58%, corresponding to a res-
tenosis of 38% when taking into account the
post-interventional angiographic minimal lumen
diameter. The cause of thrombus formation was
similar to that in case 2, namely late scaffold strut
discontinuity (Figure 2, Online Video 2), with the
particular ﬁnding of a long scaffold strut freely
ﬂoating in the lumen. Uncovered struts were
frequently observed (10%), and most struts were
covered by thrombus.ith the 3-dimensional (3D) and 2-dimensional (2D) longitudinal view (indicated by arrows
view, and F the spread-out 3D view. Case 1 shows malapposed struts surrounded by thrombus
he minimal lumen area location (C). Case 2 shows extensive scaffold strut discontinuity
raphy. Case 3 shows thrombus on top of uncovered apposed scaffold struts (A, B, arrowheads).
eo 2) surrounded by thrombus, as well as uncovered struts (C, arrowheads) in 2D and 3D optical
e scaffold strut; red is thrombus.
TABLE 3 Quantitative Optical Coherence Tomography
Case 1 Case 2 Case 3 Case 4
Lesion level
Analyzed frames in lesion 100 99 109 66
Lesion length, mm 20.0 19.8 21.8* 13.2
Reference lumen area, mm2 7.87 5.53 4.17* 7.89
Distal reference lumen area, mm2 8.51 3.47 2.49* 8.79
Proximal reference lumen area,
mm2
7.22 7.58 5.86 6.99
Minimal lumen area, mm2 1.98 1.61 2.33 3.29
Area stenosis, % 74.8 70.9 44.1* 58.3
Minimal scaffold area, mm2 4.18 2.44 3.56 4.57
Scaffold expansion, % 53.1 44.1 85.4* 57.9
Eccentricity index 0.87 0.78 0.80 0.64
Eccentricity index at the minimal
scaffold area frame
0.88 0.74 0.69 0.67
Cross-sectional level
Cross sections with lumen area 100 99 109 66
Lumen area, mm2 4.90  1.67 3.31  1.03 3.80  0.79 7.19  2.57
Frames with scaffold area 10 47 77 45
Scaffold area, mm2 5.52  1.28 3.43  0.70 4.49  0.61 7.35  2.06
Neointimal hyperplasia
area, mm2
0.54  0.21 0.98  0.27 0.92  0.69 1.00  0.52
Incomplete scaffold apposition
area, mm2
0.13  0.18 0.19  0.26 0.07  0.15 0.52  0.59
Frames with thrombus 60 84 60 47
Frames with thrombus and
scaffold
59 84 60 47
Thrombus area, mm2 0.42  0.47 0.77  1.0 1.47  1.36 0.44  0.54
Neoatherosclerosis, frames with
macrophage accumulations
10 20 0 0
Scaffold strut level
Frames with visible scaffold remnants 94 99 109 66
Struts 381 697 950 574
Strut core area, mm2 0.0195 
0.00939
0.0255 
0.144
0.0283 
0.0138
0.0347 
0.0187
Strut classiﬁcation
Preserved box 188 (49.3) 406 (58.2) 918 (96.6) 556 (96.9)
Nonpreserved box 193 (50.7) 291 (41.8) 32 (3.4) 18 (3.1)
Strut characteristics
Apposed
Covered by neointima 304 (79.8) 537 (77.0) 784 (82.5) 428 (74.6)
Neointimal thickness, mm 0.17  0.10 0.21  0.13 0.18  0.11 0.16  0.12
Uncovered, no thrombus 5 (1.3) 24 (3.4) 3 (0.3) 18 (3.1)
Uncovered, superimposed
thrombus
5 (1.3) 19 (2.7) 45 (4.7) 28 (4.9)
Possibly uncovered† 39 (10.2) 45 (6.5) 124 (13.1) 46 (8.0)
Malapposed
Malapposed uncovered 1 (0.3) 9 (1.3) 0 (0.0) 3 (0.5)
Malapposed with thrombus 27 (7.1) 63 (9.0) 2 (0.2) 51 (8.9)
Incomplete scaffold apposition
distance, mm
0.18  0.09 0.40  0.24 0.24  0.04 0.41  0.22
Values are n, mean  SD, or n (%). *As the distal edge of the scaffold was not captured in case 3, distal reference
was calculated as mean lumen area of the distal in-stent region (2 mm). †Apposed struts with overlying thrombus
layer that does not clearly allow to distinguish whether there is an additional neointimal layer underneath.
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This report investigates a series of 4 patients pre-
senting with VLScT analyzed by intracoronaryimaging, histopathological, and spectroscopic anal-
ysis. The principal ﬁndings can be summarized as
follows:
1. VLScT may occur despite antiplatelet therapy at
time intervals after device implantation when
scaffold resorption would be expected to be at
advanced stages or nearly complete.
2. Polymer resorption may not be complete in
humans as late as 4 years after device implanta-
tion, as evidenced by Fourier transform IR spec-
troscopic thrombus aspirate analysis (case 1).
3. The presence of malapposed and uncovered scaf-
fold struts in direct contact with thrombus sug-
gests a potential triggering role (all cases).
4. Scaffold discontinuity (cases 2 and 4) and reste-
nosis (cases 1 and 2) related to the resorption pro-
cess emerge as potential triggers for VLScT (Central
Illustration).
Very late metallic DES thrombosis was ﬁrst
reported in a series of 4 patients treated with ﬁrst-
generation DES in the context of antiplatelet cessa-
tion and surgical procedures (19). Subsequently, data
from large-scale observational studies and random-
ized clinical trials conﬁrmed a small but increased
risk of very late stent thrombosis (VLST) associated
with ﬁrst-generation DES compared with bare-metal
stents (20–22). Intracoronary imaging (23–26) and
histopathological analyses (27,28) were instrumental
to unravel mechanisms responsible for VLST. The
presence of uncovered and malapposed struts (26)
emerged as predictors of VLST, and delayed
arterial healing from chronic inﬂammatory re-
actions (28), hypersensitivity reactions (24), positive
remodeling, and neoatherosclerosis (25) were addi-
tional features.
Although VLST risk has been reduced with the
advent of newer-generation metallic DES (3,29,30),
fully bioresorbable scaffolds offer the potential to
overcome late thrombotic adverse events related to
the implant because of the reconstitution of vessel
anatomy and physiology in the absence of foreign
material. Using histological examination and gel
permeation chromatography, animal studies have
documented complete polymer biodegradation at 2 to
3 years (31–33). In the present study of patients
treated with the Absorb BVS 1.1, we observed pre-
served scaffold struts surrounded or covered by
thrombus at the time of VLScT, a ﬁnding suggesting a
causal link between persistent scaffold struts and
thrombus. Similarly, preserved scaffold boxes were
also seen in 3 individual case reports of VLScT pub-
lished to date (16–18). Because the OCT appearance of
preserved boxes does not exclude an advanced stage
FIGURE 4 Histological Images of Thrombus Aspirates
Case 1
Case 2
Case 3
A
B
C
Aspirates stained with hematoxylin and eosin are seen at 1.25, 5, 10, and 20 magniﬁcations. Higher magniﬁcations show platelet-rich
thrombus in cases 1 (A) and 2 (B) with a higher amount of interspersed mononuclear cells in case 2. Thrombus in case 3 (C) mainly consists of
ﬁbrin-rich thrombus.
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1909of resorption, the persistence of polymer material in 1
of the thrombus aspirates (case 1) 44 months after
device implantation is noteworthy. The observation
of polymer material 4 years after scaffold implanta-
tion, as evidenced by Fourier transform IR spectros-
copy (34), indicates an extended period during which
thrombotic events may occur, and it may have im-
plications regarding the recommended duration of
potent antiplatelet therapy (8,35).
POTENTIAL VLScT TRIGGERS. Malapposition has
been repeatedly associated with very late metallic DES
thrombosis (26,36). We observed a high frequency of
malapposed struts surrounded by thrombus in 3 cases.
Given the absence of post-procedural intracoronary
imaging in case 1, a categorization into persistentor late-acquired malapposition is not feasible.
Post-procedural intravascular ultrasound examina-
tion in case 2, however, indicated full scaffold
apposition, a ﬁnding suggesting the presence of
late-acquired malapposition. Because the scaffold
struts in cases 2 and 4 were displaced into the lumen
center, and their conﬁguration is atypical for persis-
tent malapposition, resorption-related scaffold dis-
continuity is the most likely explanation for VLScT.
This represents a novel pathomechanism in VLScT
that is different from positive vessel wall remodeling
in response to vascular inﬂammation leading to late-
acquired malapposition. It is noteworthy that OCT
failed to show evidence of coronary evaginations (37),
a ﬁnding correlated with positive remodeling (38).
FIGURE 5 Histological Images of Platelet- and Fibrin-rich Thrombus Aspirate
A
B
C
D
E
0.1 mm
0.1 mm
When stained with hematoxylin and eosin, ﬁbrin stains pink and platelets stain grayish at 10 and 20 magniﬁcation (A and C). Glycoproteins
and proteoglycans within foreign material appear purple magenta with Periodic acid–Schiff stain at 20 magniﬁcation (B). Foreign material
stains green when assessed in Movat pentachrome staining (D). Polarized light shows birefringence within foreign material at 10 magniﬁ-
cation (E). Arrows point to foreign material within aspirated thrombus.
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1910In a recent OCT substudy of ABSORB B, 42% of
lesions showed evidence of late scaffold strut
discontinuity (39). The frequency of such disconti-
nuity leading to malapposition, however, was not
reported. In all but 1 case (non–ischemia-driven
target-lesion revascularization), these ﬁndings did
not lead to clinical events.
In the metallic DES era, uncovered struts represent
a characteristic associated with delayed healing and
increased risk of stent thrombosis (40,41). In case 3,
uncovered scaffold struts emerged as the predomi-
nant ﬁnding. We carefully differentiated between
completely uncovered struts and uncovered struts
superimposed by thrombus. The latter category is
of particular interest because it suggests a direct
relationship between uncovered scaffold struts andthrombus formation. In cases 2 and 4, a high fre-
quency of uncovered scaffold struts was observed in
addition to the main ﬁnding of late strut disconti-
nuity. Only uncovered struts not immobilized by
neointima can protrude into the lumen when struc-
tural integrity is lost and subsequently cause late
scaffold strut discontinuity, a ﬁnding suggesting that
neointimal coverage may be particularly important
after implantation of BVSs.
In cases 1 and 2, lumen narrowing at the time of
VLScT was >70%. Although post-procedural angiog-
raphy is indicative of suboptimal lesion expansion in
both cases, acute recoil was low. The mechanism of
the restenosis cannot be precisely determined in the
absence of serial intravascular imaging and visuali-
zation of the external elastic membrane. Restenosis
FIGURE 6 Fourier Transform Infrared Spectroscopic Analysis
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Compared with a reference polylactic acid ﬁber (A) and Absorb (Abbott Vascular, Santa
Clara, California) bioresorbable vascular scaffold (BVS) 1.1 (B), the spectrum of the foreign
material derived from the thrombus aspirate displays similar spectroscopic bands (C).
Additionally, bands at 3,282/1,647/1,536 cm1 are consistent with protein (some particles
were attached to the foreign body).
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1911in the absence of signiﬁcant neointimal proliferation
(Figure 3) can be explained by chronic recoil, plaque
growth, or shrinkage of the external elastic
membrane.
Although neointimal hyperplasia was the only
cause of restenosis with metallic DES, restenosis in
the absence of signiﬁcant neointimal proliferation
may occur late during the BVS-related resorption
process and requires careful examination in future
studies. To what extent the presence of restenosis
contributes to formation of VLScT remains unan-
swered by our case series. Nonetheless, BVS implan-
tation requires meticulous attention to implantation
technique to ensure an optimal post-procedural
result. In the randomized ABSORB II study (11),
postprocedural acute gain and lumen dimensions
were lower in lesions treated with BVS compared with
metallic DES, largely related to a less aggressive post-
dilation strategy. Intracoronary imaging at the time of
BVS implantation may become a valuable adjunct to
identify suboptimal scaffold expansion and apposi-
tion, particularly among patients with increased
lesion complexity (42). Whether speciﬁc implantation
techniques can improve outcomes after bioresorbable
scaffold implantation remains to be shown in dedi-
cated studies.
Although the number of cases is too small to
allow for meaningful quantiﬁcation of cellular
thrombus components, it is notable that none of
the thrombus aspirates showed eosinophilic cells
(Figure 4). Previous investigations suggested eosin-
ophilic inﬁltrates as the footprint of VLST related
to sirolimus-eluting stent implantation, which also
correlated with the extent of positive remodeling.
The absence of eosinophilic cells renders hyper-
sensitivity reactions unlikely causes of VLScT in
the present series. Until larger cohort studies are
available, including histopathological analysis of
thrombus aspirates and autopsy studies, hypersen-
sitivity reactions in response to the PLLA polymer
cannot be excluded.
Neoatherosclerosis has been identiﬁed as a mech-
anism related to VLST in intracoronary imaging
cohort studies. Macrophage accumulations are
considered the earliest manifestations of neo-
atherosclerosis and were observed in cases 1 and 2.
However, no obvious correlation between neo-
atherosclerosis and thrombus formation was
observed (e.g., ﬁbrous cap rupture). Further studies
are required to determine to what extent more
advanced stages of neoatherosclerosis contribute to
VLScT pathogenesis.
Three reports of individual cases of VLScT provide
information on antiplatelet therapy at the time of the
CENTRAL ILLUSTRATION Potential Mechanisms in the Pathogenesis of Very Late Scaffold Thrombosis
Neointima
                      Complete ResorptionScaffold Implantation
Scaffold Resorption
Late Scaffold Discontinuity
 Scaffold Thrombosis                                                                                                     Restenosis
Räber, L. et al. J Am Coll Cardiol. 2015; 66(17):1901–14.
Uneventful scaffold resorption results in positive remodeling with lumen expansion, intact intima, and normal vessel hemodynamics (upper right). In the
presence of relevant areas of malapposed or uncovered scaffold struts, late scaffold discontinuity may cause dislocation of strut remnants into the lumen.
This may lead to disturbed hemodynamic ﬂow and activation of the thrombotic cascade potentially that result in very late scaffold thrombosis (lower left).
Restenosis in the absence of relevant neointimal hyperplasia represents another potential mechanism in very late scaffold thrombosis (lower right).
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1912adverse event. In 2 cases, antiplatelet therapy was
insufﬁcient: this was related to cessation of both
aspirin and clopidogrel (18) and resulted from oral
anticoagulation with warfarin only, including a sub-
therapeutic international normalized ratio (16). In
another case, VLScT occurred 4 days after DAPT
discontinuation (17). In contrast, all patients pre-
senting with VLScT in this report were receiving sin-
gle antiplatelet therapy with low-dose aspirin (cases 1
and 2) or taking DAPT with aspirin and prasugrel
(cases 3 and 4) at the time of thrombosis. Therefore,it is unlikely that more intense antiplatelet therapy
would have prevented the observed thrombotic
events.
STUDY LIMITATIONS. This is an observational study
based on 4 cases with sophisticated analyses, and the
ﬁndings should be considered hypothesis generating.
Nevertheless, we consider the observations clinically
relevant because they suggest new mechanisms
involved in very late thrombosis after scaffold im-
plantation. Although unlikely, we cannot exclude
that some of the documented alterations visualized
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Thrombosis of
bioresorbable coronary scaffolds may occur at late stages of the
resorption process despite antiplatelet therapy, possibly related
to scaffold discontinuity and restenosis. This ﬁnding implies an
extended period of vulnerability to ischemic events.
TRANSLATIONAL OUTLOOK: Further research is required to
conﬁrm the mechanisms responsible for late scaffold thrombosis,
deﬁne requisite antithrombotic therapeutic strategies, and
develop improved devices to reduce the risk of ischemic events.
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1913by OCT were caused by the thrombus aspiration pro-
cedure. Moreover, in the absence of serial intra-
vascular imaging and intravascular ultrasound
measurements, the mechanism of restenosis could
not be fully elucidated. This study is not able to
provide reliable data regarding the incidence of
VLScT, given the limited number of patients under-
going treatment with the Absorb BVS at the 3
institutions and the lack of prespeciﬁed patient
and lesion criteria pertaining to the use of the Absorb
BVS.
CONCLUSIONS
VLScT may occur at advanced stages of scaffold
resorption. Potential mechanisms speciﬁc for VLScT
include scaffold discontinuity and restenosis during
the resorption process, which may be delayed in
humans, suggesting an extended period of vulnera-
bility for thrombotic events.REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Stephan Windecker, Department of Cardiology, Bern
University Hospital, Freiburgstrasse, 3010 Bern,
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